Mycotoxins and human disease: A largely ignored global health issue

Carcinogenesis

Volumn 31, Issue 1, 2009, Pages 71-82

  Wild, Christopher P ^a   Gong, Yun Yun ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; BIOLOGICAL MARKER; FUMONISIN; MYCOTOXIN; SPHINGOLIPID; SPHINGOSINE ACYLTRANSFERASE; CARCINOGEN;

AFLATOXICOSIS; AFRICA; ASIA; CARCINOGENESIS; CARCINOGENICITY; CEREAL; COMORBIDITY; ESOPHAGUS CANCER; EXPOSURE; FOOD CONTAMINATION; FOOD INTAKE; GROWTH DISORDER; HEPATITIS B; HUMAN; IMMUNOMODULATION; INTOXICATION; KIDNEY CANCER; LIVER CELL CARCINOMA; MAIZE; METABOLISM; MUTAGENESIS; NEURAL TUBE DEFECT; NONHUMAN; PEANUT; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RODENT; SECONDARY PREVENTION; SOUTH AND CENTRAL AMERICA; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; ENVIRONMENTAL EXPOSURE; LIVER TUMOR;

ANIMALS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; ENVIRONMENTAL EXPOSURE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MYCOTOXINS;

EID: 74049147153     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp264     Document Type: Review

References (130)

1. Council for Agricultural Science and Technology. (2003) Mycotoxins: Risks in Plant, Animal, and Human Systems. Task Force Report No. 139. CAST, Ames, IA.
2. Azziz-Baumgartner, E. et al. (2005) Case-control study of an acute aflatoxicosis outbreak, Kenya, 2004. Environ. Health Perspect., 113, 1779-1783.
3. Programme on Mycotoxins and Experimental Carcinogenesis (PROMEC Unit). (2001) Aflatoxin in Peanut Butter. Policy Brief No. 3 May 2001. http://www.mrc.ac.za/policybriefs/polbrief3.htm. (2 October 2009, date last accessed). South African Medical Research Council, Tygerberg, South Africa.
4. Wild, C.P. (2007) Aflatoxin exposure in developing countries: the critical interface of agriculture and health. Food Nutr. Bull., 28, S372-S380.
5. Strosnider, H. et al. (2006) Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ. Health Perspect., 114, 1898-1903.
6. IARC. (2002) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. International Agency for Research on Cancer, Lyon, 301-366.
7. Williams, J.H. et al. (2004) Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am. J. Clin. Nutr., 80, 1106-1122.
8. Wild, C.P. et al. (2002) The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis, 17, 471-481.
9. Bailey, E.A. et al. (1996) Mutational properties of the primary aflatoxin B-1-DNA adduct. Proc. Natl Acad. Sci. USA, 93, 1535-1539.
10. Smela, M.E. et al. (2002) The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc. Natl Acad. Sci. USA, 99, 6655-6660.
11. Brown, K.L. et al. (2006) Unraveling the aflatoxin-FAPY conundrum: structural basis for differential replicative processing of isomeric forms of the formamidopyrimidine-type DNA adduct of aflatoxin B1. J. Am. Chem. Soc., 128, 15188-15199.
12. Kamdem, L.K. et al. (2006) Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem. Res. Toxicol., 19, 577-586.
13. Wojnowski, L. et al. (2004) Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics, 14, 691-700.
14. Kamataki, T. et al. (1995) Expression of CYP3A7, a human fetus-specific cytochrome P450, in cultured cells and in the hepatocytes of p53-knockout mice. Toxicol. Lett., 82-83, 879-882.
15. Guengerich, F.P. et al. (1998) Activation and detoxication of aflatoxin B1. Mutat. Res., 402, 121-128.
16. Johnson, D.N. et al. (2008) Quantification of urinary aflatoxin B1 dialdehyde metabolites formed by aflatoxin aldehyde reductase using isotope dilution tandem mass spectrometry. Chem. Res. Toxicol., 21, 752-760.
17. Groopman, J.D. et al. (2008) Protective interventions to prevent aflatoxininduced carcinogenesis in developing countries. Annu. Rev. Public Health, 29, 187-203.
18. Hussain, S.P. et al. (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene, 26, 2166-2176.
19. Kirk, G.D. et al. (2005) 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene, 24, 5858-5867.
20. Jackson, P.E. et al. (2001) Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res., 61, 33-35.
21. Allen, S.J. et al. (1992) Aflatoxin exposure, malaria and hepatitis-B infection in rural Gambian children. Trans. R. Soc. Trop. Med. Hyg., 86, 426-430.
22. Turner, P.C. et al. (2000) Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop. Med. Int. Health, 5, 837-841.
23. Turner, P.C. et al. (2003) Modification of immune function through exposure to dietary aflatoxin in Gambian children. Environ. Health Perspect., 111, 217-220.
24. Turner, P.C. et al. (2007) Aflatoxin exposure in utero causes growth faltering in Gambian infants. Int. J. Epidemiol., 36, 1119-1125.
25. Gong, Y.Y. et al. (2002) Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study. Br. Med. J., 325, 20-21.
26. Gong, Y.Y. et al. (2003) Determinants of aflatoxin exposure in young children from Benin and Togo, West Africa: the critical role of weaning. Int. J. Epidemiol., 32, 556-562.
27. Turner, P.C. et al. (2005) Absence of TP53 codon 249 mutations in young Guinean children with high aflatoxin exposure. Cancer Epidemiol. Biomarkers Prev., 14, 2053-2055.
28. Turner, P.C. et al. (2005) Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet, 365, 1950-1956.
29. Diallo, M.S. et al. (2009) Prevalence of exposure to aflatoxin and hepatitis B and C viruses in Guinea, West Africa. Nat. Toxins, 3, 6-9.
30. McCoy, L.F. et al. (2008) Human aflatoxin albumin adducts quantitatively compared by ELISA, HPLC with fluorescence detection, and HPLC with isotope dilution mass spectrometry. Cancer Epidemiol. Biomarkers Prev., 17, 1653-1657.
31. Wild, C.P. et al. (1992) Field studies of aflatoxin exposure, metabolism and induction of genetic alterations in relation to HBV infection and hepatocellular carcinoma in The Gambia and Thailand. Toxicol. Lett., 64-65. Spec No. 455-461.
32. Wild, C.P. et al. (2000) Environmental and genetic determinants of aflatoxinalbumin adducts in the Gambia. Int. J. Cancer, 86, 1-7.
33. Parkin, D.M. (2006) The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer, 118, 3030-3044.
34. Qian, G.S. et al. (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 3, 3-10.
35. Wang, L.Y. et al. (1996) Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer, 67, 620-625.
36. Ross, R.K. et al. (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339, 943-946.
37. Sun, C.A. et al. (2001) Genetic polymorphisms of glutathione Stransferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested casecontrol study in Taiwan. Carcinogenesis, 22, 1289-1294.
38. Chen, C.J. et al. (1996) Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology, 24, 38-42.
39. Sun, Z. et al. (1999) Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology, 30, 379-383.
40. Yu, M.W. et al. (1997) Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J. Hepatol., 27, 320-330.
41. Wu, H.C. et al. (2009) Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol. Biomarkers Prev., 18, 846-853.
42. Omer, R.E. et al. (2004) Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma. Nutr. Cancer, 48, 15-21.
43. Kuniholm, M.H. et al. (2008) Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ. Health Perspect., 116, 1553-1557.
44. Chen, C.H. et al. (2007) Aflatoxin exposure and hepatitis C virus in advanced liver disease in a hepatitis C virus endemic area in Taiwan. Am. J. Trop. Med. Hyg., 77, 747-752.
45. Wild, C.P. et al. (2009) A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. (epub ahead of print).
46. Lasky, T. et al. (1997) Hepatocellular carcinoma p53 G > T transversions at codon 249: the fingerprint of aflatoxin exposure? Environ. Health Perspect., 105, 392-397.
47. Kuang, S.Y. et al. (2004) Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc. Natl Acad. Sci. USA, 101, 3575- 3580.
48. Stettler, P.M. et al. (2001) Liver carcinogen aflatoxin B1 as an inducer of mitotic recombination in a human cell line. Mol. Carcinog., 31, 125-138.
49. Kaplanski, C. et al. (1997) Minisatellite rearrangements are increased in liver tumours induced by transplacental aflatoxin B1 treatment of hepatitis B virus transgenic mice, but not in spontaneously arising tumours. Carcinogenesis, 18, 633-639.
50. Fujimoto, Y. et al. (1994) Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res., 54, 281-285.
51. Wong, N. et al. (2000) Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin. Cancer Res., 6, 4000-4009.
52. Pineau, P. et al. (2008) Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat. Res., 653, 6-13.
53. Sell, S. (2003) Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res., 63, 7553-7562.
54. Sell, S. et al. (1991) Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res., 51, 1278-1285.
55. Ghebranious, N. et al. (1998) The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology, 27, 967-973.
56. Lian, M. et al. (2006) Hepatitis B virus x gene and cyanobacterial toxins promote aflatoxin B1-induced hepatotumorigenesis in mice.World J. Gastroenterol., 12, 3065-3072.
57. Madden, C.R. et al. (2002) Altered DNA mutation spectrum in aflatoxin B1-treated transgenic mice that express the hepatitis B virus x protein. J. Virol., 76, 11770-11774.
58. Tong, W.M. et al. (2006) Aflatoxin-B exposure does not lead to p53 mutations but results in enhanced liver cancer of Hupki (human p53 knock-in) mice. Int. J. Cancer, 119, 745-749.
59. Liu, Z..M.. et al. (2008) Hepatitis B virus infection contributes to oxidative stress in a population exposed to aflatoxin B1 and high-risk for hepatocellular carcinoma. Cancer Lett., 263, 212-222.
60. Sohn, S. et al. (2000) Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. Mutat. Res., 460, 17-28.
61. Barraud, L. et al. (1999) Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure. Hepatology, 29, 1317-1323.
62. Banerjee, R. et al. (2000) Effects of carcinogen-induced transcription factors on the activation of hepatitis B virus expression in human hepatoblastoma HepG2 cells and its implication on hepatocellular carcinomas. Hepatology, 32, 367-374.
63. Hall, A.J. et al. (1994) Epidemiology of aflatoxin-related disease. In Eaton, D.A. and Groopman, J.D. (eds.) The Toxicology of Aflatoxins. Academic Press, San Diego, CA, pp. 233-258.
64. Krishnamachari, K.A. et al. (1975) Hepatitis due to aflatoxicosis. An outbreak in West India. Lancet, 1, 1061-1063.
65. Ngindu, A. et al. (1982) Outbreak of acute hepatitis caused by aflatoxin poisoning in Kenya. Lancet, 1, 1346-1348.
66. Meissonnier, G.M. et al. (2008) Immunotoxicity of aflatoxin B1: impairment of the cell-mediated response to vaccine antigen and modulation of cytokine expression. Toxicol. Appl. Pharmacol., 231, 142-149.
67. Jiang, Y. et al. (2005) Aflatoxin B1 albumin adduct levels and cellular immune status in Ghanaians. Int. Immunol., 17, 807-814.
68. Jiang, Y. et al. (2008) Aflatoxin-related immune dysfunction in health and in human immunodeficiency virus disease. Clin. Dev. Immunol., 2008, 790309.
69. Gong, Y.Y. et al. (2008) Aflatoxin exposure and impaired child growth in West Africa: an unexplored international public health burden?. In Leslie, J.F., Bandyopadhyay, R. and Visconti, A. (eds.) Mycotoxins. Detection Methods, Management, Public Health and Agricultural Trade. CABI, Wallingford, Oxfordshire, UK, pp. 53-65.
70. Marasas, W.F. (2001) Discovery and occurrence of the fumonisins: a historical perspective. Environ. Health Perspect., 109 (suppl. 2), 239-243.
71. Voss, K.A. et al. (2007) Fumonisins: toxicokinetics, mechanism of action and toxicity. Anim. Feed Sci. Technol., 137, 299-325.
72. Stockmann-Juvala, H. et al. (2008) A review of the toxic effects and mechanisms of action of fumonisin B1. Hum. Exp. Toxicol., 27, 799-809.
73. Placinta, C.M. et al. (1999) A review of worldwide contamination of cereal grains and animal feed with Fusarium mycotoxins. Anim. Feed Sci. Technol., 78, 21-37.
74. De La Campa, R. et al. (2005) Modeling effects of environment, insect damage, and Bt genotypes on fumonisin accumulation in maize in Argentina and the Philippines. Mycopathologia, 159, 539-552.
75. Gelderblom, W.C. et al. (1988) Fumonisins-novel mycotoxins with cancer-promoting activity produced by Fusarium moniliforme. Appl. Environ. Microbiol., 54, 1806-1811.
76. Gelderblom, W.C. et al. (1991) Toxicity and carcinogenicity of the Fusarium moniliforme metabolite, fumonisin B1, in rats. Carcinogenesis, 12, 1247-1251.
77. Howard, P.C. et al. (2001) Fumonisin b1 carcinogenicity in a two-year feeding study using F344 rats and B6C3F1 mice. Environ. Health Perspect., 109 (suppl. 2), 277-282.
78. Gelderblom, W.C. et al. (2004) Fumonisin contamination of a corn sample associated with the induction of hepatocarcinogenesis in rats-role of dietary deficiencies. Food Chem. Toxicol., 42, 471-479.
79. Merrill, A. H. Jr et al. (2001) Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. Environ. Health Perspect., 109 (suppl. 2), 283-289.
80. Ehrlich, V. et al. (2002) Fumonisin B(1) is genotoxic in human derived hepatoma (HepG2) cells. Mutagenesis, 17, 257-260.
81. Domijan, A.M. et al. (2006) Standard and Fpg-modified comet assay in kidney cells of ochratoxin A- and fumonisin B(1)-treated rats. Toxicology, 222, 53-59.
82. Abel, S. et al. (1998) Oxidative damage and fumonisin B1-induced toxicity in primary rat hepatocytes and rat liver in vivo 1292. Toxicology, 131, 121-131.
83. Voss, K.A. et al. (2006) The role of tumor necrosis factor alpha and the peroxisome proliferator-activated receptor alpha in modulating the effects of fumonisin in mouse liver. Toxicology, 222, 165-174.
84. Riley, R.T. et al. (2001) Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis. Environ. Health Perspect., 109 (suppl. 2), 301-308.
85. Voss, K.A. et al. (2002) Carcinogenicity and mechanism of action of fumonisin B1: a mycotoxin produced by Fusarium moniliforme (= F. verticillioides). Cancer Detect. Prev., 26, 1-9.
86. Taranu, I. et al. (2005) Mycotoxin fumonisin B1 alters the cytokine profile and decreases the vaccinal antibody titer in pigs. Toxicol. Sci., 84, 301-307.
87. Fifty-sixth Report of the Joint FAO/WHO Committee on Food Additives. (2002) Evaluation of certain mycotoxins in food. Tech. Rep. Series No. 906. World Health Organization, Geneva, Switzerland.
88. Turner, P.C. et al. (1999) Fumonisin contamination of food: progress in development of biomarkers to better assess human health risks. Mutat. Res., 443, 81-93.
89. Shephard, G.S. et al. (2007) Biomarkers of exposure to fumonisin mycotoxins: a review. Food Addit. Contam., 24, 1196-1201.
90. Cai, Q. et al. (2007) Validation of fumonisin biomarkers in F344 rats. Toxicol. Appl. Pharmacol., 225, 28-39.
91. Castegnaro, M. et al. (1996) Development of a new method for the analysis of sphinganine and sphingosine in urine and tissues. Nat. Toxins., 4, 284-290.
92. Van der Westhuizen, L. et al. (1999) Sphinganine/sphingosine ratio in plasma and urine as a possible biomarker for fumonisin exposure in humans in rural areas of Africa. Food Chem. Toxicol., 37, 1153-1158.
93. Solfrizzo, M. et al. (2004) Comparison of urinary sphingolipids in human populations with high and low maize consumption as a possible biomarker of fumonisin dietary exposure. Food Addit. Contam., 21, 1090-1095.
94. Qiu, M. et al. (2001) Determination of sphinganine, sphingosine and Sa/So ratio in urine of humans exposed to dietary fumonisin B1. Food Addit. Contam., 18, 263-269.
95. Nikiema, P.A. et al. (2008) Fumonisin exposure and the sphinganine/ sphingosine ratio in urine, serum and buccal cells in adults from Burkina Faso, West Africa. World Mycotoxin J., 1, 483-491.
96. Zitomer, N.C. et al. (2009) Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J. Biol. Chem., 284, 4786-4795.
97. Shephard, G.S. et al. (1994) Determination of the mycotoxin fumonisin B1 and identification of its partially hydrolysed metabolites in the faeces of non-human primates. Food Chem. Toxicol., 32, 23-29.
98. Chelule, P.K. et al. (2001) Exposure of rural and urban populations in KwaZulu Natal, South Africa, to fumonisin B(1) in maize. Environ. Health Perspect., 109, 253-256.
99. Sewram, V. et al. (2003) Fumonisin mycotoxins in human hair. Biomarkers, 8, 110-118.
100. Gong, Y.Y. et al. (2008) Association between tortilla consumption and human urinary fumonisin B1 levels in a Mexican population. Cancer Epidemiol. Biomarkers Prev., 17, 688-694.
101. Sun, G. et al. (2007) Fumonisin B1 contamination of home-grown corn in high-risk areas for esophageal and liver cancer in China. Food Addit. Contam., 24, 181-185.
102. Franceschi, S. et al. (1990) Maize and risk of cancers of the oral cavity, pharynx, and esophagus in northeastern Italy. J. Natl Cancer Inst., 82, 1407-1411.
103. Abnet, C.C. et al. (2001) Sphingolipids as biomarkers of fumonisin exposure and risk of esophageal squamous cell carcinoma in china. Cancer Causes Control, 12, 821-828.
104. Gelderblom, W.C. et al. (2002) Interaction of fumonisin B(1) and aflatoxin B(1) in a short-term carcinogenesis model in rat liver. Toxicology, 171, 161-173.
105. Li, F.Q. et al. (2001) Aflatoxins and fumonisins in corn from the highincidence area for human hepatocellular carcinoma in Guangxi, China. J. Agric. Food Chem., 49, 4122-4126.
106. Ueno, Y. et al. (1997) Fumonisins as a possible contributory risk factor for primary liver cancer: a 3-year study of corn harvested in Haimen, China, by HPLC and ELISA. Food Chem. Toxicol., 35, 1143-1150.
107. Gelineau-van, W.J. et al. (2005) Maternal fumonisin exposure and risk for neural tube defects: mechanisms in an in vivo mouse model. Birth Defects Res. A Clin. Mol. Teratol., 73, 487-497.
108. Marasas, W.F.O. et al. (2004) Fumonisins disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisin-contaminated maize. J. Nutr., 134, 711-716.
109. Hendricks, K. (1999) Fumonisins and neural tube defects in South Texas 1294. Epidemiology, 10, 198-200.
110. Missmer, S.A. et al. (2006) Exposure to fumonisins and the occurrence of neural tube defects along the Texas-Mexico border. Environ. Health Perspect., 114, 237-241.
111. Shephard, G.S. et al. (2007) Exposure assessment for fumonisins in the former Transkei region of South Africa. Food Addit. Contam., 24, 621-629.
112. Nikiema, P.A. et al. (2004) Fumonisin contamination of maize in Burkina Faso, West Africa. Food Addit. Contam., 21, 865-870.
113. Torres, O.A. et al. (2007) Estimated fumonisin exposure in Guatemala is greatest in consumers of lowland maize. J. Nutr., 137, 2723-2729.
114. Kimanya, M.E. et al. (2009) Exposure of infants to fumonisins in maizebased complementary foods in rural Tanzania. Mol. Nutr. Food Res., 53, 667-674.
115. Wild, C.P. et al. (2000) Primary prevention of hepatocellular carcinoma in developing countries. Mutat. Res., 462, 381-393.
116. Munkvold, G.P. (2003) Cultural and genetic approaches to managing mycotoxins in maize. Ann. Rev. Phytopathol., 41, 99-116.
117. Humpf, H.U. et al. (2004) Effects of thermal food processing on the chemical structure and toxicity of fumonisin mycotoxins. Mol. Nutr. Food Res., 48, 255-269.
118. International Institute for Applied Systems Analysis (IIASA). (2009) How did China's Grain Supply Change Between 1964-1966 and 1994-1996. http://www.iiasa.ac.at/Research/LUC/ChinaFood/indepth/id_htm. (2 October 2009, last date accessed).
119. Shephard, G.S. (2008) Impact of mycotoxins on human health in developing countries. Food Addit. Contam., 25, 146-151.
120. Kimanya, M.E. et al. (2008) Co-occurrence of fumonisins with aflatoxins in home-stored maize for human consumption in rural villages of Tanzania. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess., 25, 1353-1364.
121. Burns, T.D. et al. (2008) Fumonisin concentrations and in vivo toxicity of nixtamalized Fusarium verticillioides culture material: evidence for fumonisin-matrix interactions. Food Chem. Toxicol., 46, 2841-2848.
122. Seiferlein, M. et al. (2007) Hydrolyzed fumonisins HFB1 and HFB2 are acylated in vitro and in vivo by ceramide synthase to form cytotoxic N-acyl-metabolites. Mol. Nutr. Food Res., 51, 1120-1130.
123. Palencia, E. et al. (2003) Total fumonisins are reduced in tortillas using the traditional nixtamalization method of mayan communities. J. Nutr., 133, 3200-3203.
124. Fandohan, P. et al. (2005) Natural occurrence of Fusarium and subsequent fumonisin contamination in preharvest and stored maize in Benin, West Africa. Int. J. Food Microbiol., 99, 173-183.
125. Wang, P. et al. (2008) NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis: II. Reduction in biomarkers of aflatoxin exposure in blood and urine. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess., 25, 622-634.
126. Tang, L. et al. (2008) Modulation of aflatoxin biomarkers in human blood and urine by green tea polyphenols intervention. Carcinogenesis, 29, 411-417.
127. Alston, J.M. et al. (2009) Agriculture. Agricultural research, productivity, and food prices in the long run. Science, 325, 1209-1210.
128. Wu, F. (2004) Mycotoxin risk assessment for the purpose of setting international regulatory standards. Environ. Sci. Technol., 38, 4049-4055.
129. Wu, F. et al. (2009) Health economic impacts and cost-effectiveness of aflatoxin reduction strategies in Africa: case studies in biocontrol and postharvest interventions. Food Addit. Contam. in press.
130. Jolly, C.M. et al. (2009) Risks of ingestion of aflatoxin-contaminated groundnuts in Benin: scale measurements, beliefs, and socioeconomic factors. Risk Anal., 29, 1395-1409.